In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CureDM Group Holdings, LLC

Latest From CureDM Group Holdings, LLC

Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds

Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.

Financing Innovation

TCT 2017: Fewer Stents Are Better Than More For Initial AMI-With-Shock Treatment

Results of the CULPRIT-SHOCK trial presented at the Transcatheter Cardiovascular Therapeutics conference in Denver confirm that patients with acute myocardial infarction complicated by cardiogenic shock are better off treated with culprit-lesion-only percutaneous coronary intervention rather than multivessel stenting, which is currently recommended in the European guidelines.

Cardiology Clinical Trials

Experts Call For More Clinical Trials Of Percutaneous Circulatory Devices

A new multi-society clinical expert consensus statement on percutaneous mechanical circulatory support is intended to help physicians select devices for the patients who are most likely to benefit, but the authors identify several questions about the devices that need to be addressed in future clinical studies.

Medical Device

Beta/Islet Cell Regeneration Leads Diabetes Deal-Making This Decade

A review of deal-making in the diabetes space since 2010 finds deals around technology to regenerate pancreatic beta cells and/or islet cells as the hottest mechanism of action. Thirteen deals in this area out-number the combined deals involving the DPP-4, SGLT-2 and GLP-1 mechanisms during that period.

BioPharmaceutical Deals
See All

Company Information